Beyond GLP-1: A brief review of Next-Generation Emerging Obesity Therapeutics
The therapeutic landscape for obesity management is rapidly evolving. While glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and tirzepatide (a dual GIP/GLP-1 agonist) have revolutionized care, the pipeline is advancing toward novel mechanisms offering potential for enhanced efficacy, tolerability, and convenience. For the healthcare professional, understanding these emerging targets is key to anticipating future treatment […]
